Ranbaxy Shutters New York Liquids Unit Citing Rationalization, Keeps Optimism On Lipitor Exclusivity
This article was originally published in The Pink Sheet Daily
Executive Summary
The unit, part of the larger Ohm Labs facility, was the focus of an FDA warning to Ranbaxy last year to undertake comprehensive assessment of all its manufacturing sites for GMP compliance.